

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

INSIDE INFORMATION

POSITIVE PROFIT ALERT FOR THE SIX MONTHS ENDED 30 JUNE 2021

This announcement is made by IVD Medical Holding Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the latest available information and a preliminary assessment of the Group’s unaudited consolidated management accounts for the six months ended 30 June 2021 (the “**Reporting Period**”), it is expected that the Group will record (i) an increase in revenue by approximately 20%; (ii) a significant increase in profit attributable to owners of the parent of the Group by more than 100%; and (iii) a significant increase in adjusted profit attributable to owners of the parent of the Group (Note) by more than 40%, for the Reporting Period as compared to those of the six months ended 30 June 2020.

The increase in revenue, profit attributable to owners of the parent of the Group and adjusted profit attributable to owners of the parent of the Group for the Reporting Period was primarily attributable to (i) the recovery in end customers’ demand for in vitro diagnostic (“**IVD**”) products as the operation of hospitals got back to normal when impact of the coronavirus disease diminished, which had a positive influence on the profitability of the Group’s IVD products distribution business and (ii) the increase in gross profit margin.

As at the date of this announcement, the Group is still in the process of preparing its unaudited consolidated interim results for the Reporting Period and is not able at this time to disclose any further details on the above factors. The information contained in this announcement is only based on the Board's preliminary assessment with reference to the unaudited consolidated management accounts of the Group for the Reporting Period and information currently available to the Board, which have not been reviewed or confirmed by the Company's auditors and/or the audit committee of the Company and are subject to changes. Shareholders and potential investors should refer to and review the unaudited consolidated interim results for the Reporting Period, which will be published by the Company pursuant to the requirements of the Listing Rules in due course.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Adjusted profit attributable to owners of the parent is a non-GAAP financial measure and is calculated by profit attributable to owners of the parent excluding expenses in relation to issue of new shares and expenses in relation to share options. Adjusted profit of the Group is used to exclude the impact of non-operating items which affect the results presented in the financial statements but are not indicative of the operating performance of the Group, so as to provide the Shareholders and potential investors with useful supplementary information to assess the performance of the Group's core operations.

By order of the Board
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 13 July 2021

As at the date of this announcement, the Board comprises of three executive directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, three non-executive directors, namely, Mr. Chen Xingang, Mr. Yang Zhaoxu, and Mr. Chan Kwok King, Kingsley and three independent non-executive directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.